New drug IBI362 tested for teen obesity in first pediatric trial

NCT ID NCT06536023

Completed Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested the safety and tolerability of a new drug called IBI362 in 36 Chinese adolescents aged 12 to 17 with obesity. Participants had not lost much weight through diet and exercise alone. The trial was randomized, double-blind, and placebo-controlled, meaning some got the drug and some got a dummy shot, and neither they nor the doctors knew who got what. The main goal was to check for side effects and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI362 (a drug for weight management)
What this could lead to: If successful, this could lead to a new weight-loss medication for teenagers with obesity.
What could go wrong: This is an early Phase 1 trial with only 36 participants, focused on safety and dosing. It is too small to prove effectiveness, and the drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADOLESCENTS WITH OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADOLESCENTS WITH OBESITY

Contacts and locations

Locations

Beijing Children's Hospital, Capital Medical University Affiliated

Beijin, Beijin, 100045, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.